Researchers discover TGF-beta and RAS pathways’ roles in the development of lung adenocarcinoma.
A recent study led by researchers from Memorial Sloan Kettering Cancer Center (MSK) has made significant progress in understanding the mechanisms behind the metastasis of lung adenocarcinoma, a common and deadly form of lung cancer. Metastasis, the process by which cancer cells spread from their original site to other parts of the body, is responsible for nearly 90% of cancer-related deaths worldwide. The study, published on September 6 in Cell, sheds light on two key signaling pathways – TGF-beta and RAS – that are instrumental in enabling cancer cells to metastasize. This discovery opens the door to potential new treatment strategies aimed at halting metastasis, offering hope for more effective interventions.
Lung adenocarcinoma is the most common type of lung cancer, and metastasis is a primary reason for its high mortality rate. The findings from this research suggest that targeting either the TGF-beta or RAS signaling pathways could help prevent the cancer from spreading. The TGF-beta signaling pathway, in particular, plays a critical role in the process of metastasis. TGF-beta, a multifunctional cytokine involved in regulating cellular functions such as tissue repair and embryonic development, is co-opted by cancer cells to aid their invasion into other tissues. However, its full metastatic potential is unlocked when working in conjunction with the RAS pathway, which is responsible for regulating cell growth, proliferation, and differentiation.
Jun Ho Lee, PhD, the lead author of the study, highlighted the importance of this research, stating, “Preventing metastasis offers immense potential for saving lives, given its role in the majority of cancer fatalities.” He emphasized that by understanding how these pathways collaborate to drive the metastatic process, researchers can develop targeted therapies to inhibit their function and prevent the spread of cancer.
The TGF-beta pathway, under normal circumstances, has a dual function: it promotes tissue regeneration and inhibits tumor growth. However, in the case of cancer, this pathway is hijacked by malignant cells, allowing them to escape normal growth control mechanisms and move to distant organs. This transformation of the TGF-beta pathway from tumor suppressor to metastasis promoter marks a pivotal shift in cancer progression. Simultaneously, the RAS pathway plays an equally crucial role. The study uncovered that a protein called RAS response element binding protein 1 (RREB1), which is regulated by the RAS pathway, interacts with SMAD4, a component of the TGF-beta pathway. Together, these molecules drive the metastatic process, particularly in lung cancer.
Despite TGF-beta’s critical role in cancer progression, it presents challenges as a therapeutic target. Because TGF-beta is involved in numerous essential biological processes, inhibiting it entirely could lead to significant side effects, such as autoimmune diseases and chronic inflammation. Dr. Joan Massagué, the senior author of the study and Director of the Sloan Kettering Institute, explained, “TGF-beta helps maintain healthy tissues, but in cancer, it accelerates malignancy. This paradox has fueled much of our research.” By examining how the RAS and TGF-beta pathways interact, the research team aims to develop more selective therapies that target cancer cells without disrupting normal tissue functions.
The implications of this research extend beyond lung adenocarcinoma. The TGF-beta and RAS pathways are also involved in other types of cancer, as well as non-cancerous conditions such as fibrosis. Fibrosis, the formation of excess scar tissue, shares similar signaling pathways with cancer metastasis. The research may provide insights into treating lung fibrosis, a condition that has gained more attention recently due to its association with long-term complications from COVID.
Ultimately, this study represents a significant step forward in the fight against cancer metastasis. By targeting the interplay between TGF-beta and RAS, researchers are working toward developing therapies that could prevent the spread of cancer, thereby improving outcomes for patients with lung adenocarcinoma and potentially other cancer types. While challenges remain in translating these findings into clinical treatments, the research provides a promising foundation for future advancements in cancer care.
Sources:
TGF-β and RAS jointly unmask primed enhancers to drive metastasis: Cell
Join the conversation!